Clinical Trial Update: Molecular Imaging With Erlotinib and Bevacizumab [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating molecular imaging with erlotinib and bevacizumab in non-small cell lung cancer. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Tarceva (erlotinib)

Snippet

Sponsor: University of Cologne | Conditions: Non-Small-Cell Lung Carcinoma | Phase 2 | Status: COMPLETED